$2.200
+0.184 (+8.37%)收盘时
- High
- 2.320
- Open
- 2.020
- VWAP
- 2.16
- Vol
- 188.26K
- Mkt Cap
- —
- Low
- 1.960
- Amount
- 406.66K
- EV/EBITDA, TTM
- 0.00
NAYA Biosciences, Inc. formerly INVO Bioscience, Inc. operates the fertility business, as well as its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. It offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
估值指标
事件时间线
资讯
3.512-10BusinesswireNayaPay Partners with Alipay+ to Launch Global QR Payments
2.005-01TipRanks3 Penny Stocks to Watch Now, 5/1/25
4.504-24NewsfilterINVO Fertility Confirms New Nasdaq Trading Symbol of "IVF"
9.504-15BenzingaWhy Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
8.504-15SeekingAlphaNAYA Biosciences to separate fertility and oncology businesses into distinct operations, changes name to INVO Fertility
NAYA FAQ — answered by Alphio AI
NAYA Biosciences, Inc. formerly INVO Bioscience, Inc. operates the fertility business, as well as its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. It offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process. It operates in the Healthcare sector.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。